TG Therapeutics Inc’s (NASDAQ: TGTX) Stock Prices May Increase Drastically In The Near Future.

In the last trading session, 3.22 million shares of the TG Therapeutics Inc (NASDAQ:TGTX) were traded, and its beta was 2.31. Most recently the company’s share price was $14.25, and it changed around $0.15 or 1.06% from the last close, which brings the market valuation of the company to $2.20B. TGTX currently trades at a discount to its 52-week high of $35.67, offering almost -150.32% off that amount. The share price’s 52-week low was $6.46, which indicates that the current value has risen by an impressive 54.67% since then. We note from TG Therapeutics Inc’s average daily trading volume that its 3-month average coming to 3.50 million.

TG Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.62. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended TGTX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. TG Therapeutics Inc is expected to report earnings per share of -$0.04 for the current quarter.

TG Therapeutics Inc (NASDAQ:TGTX) trade information

Instantly TGTX has showed a green trend with a performance of 1.06% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently down -16.57% year-to-date, but still up 1.79% over the last five days. On the other hand, TG Therapeutics Inc (NASDAQ:TGTX) is -8.01% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $18.4, which translates to bulls needing to increase their stock price by 22.55% from its current value. Analyst projections state that TGTX is forecast to be at a low of $5 and a high of $24.

TG Therapeutics Inc (TGTX) estimates and forecasts

TG Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 111.11 percent over the past six months and at a -233.33% annual growth rate that is well below the industry average of 18.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 85.70% in revenue this quarter, and will report an increase of 79.40% in the next quarter. The year-over-year growth rate is expected to be 12.90%, up from the previous year.

Consensus estimates provided by 7 financial analysts predict the company will bring in an average of $54.58 million in revenue for the current quarter. 7 analysts expect TG Therapeutics Inc to make $56.56 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $7.8 million and $17.45 million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 599.50%. Forecasts for the next quarter put sales growth at 224.10%.